Dyadic International, Inc. (DYAI) Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 Transcript

Dyadic International, Inc. ( DYAI) IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 December 9, 2025 9:30 AM EST Good day, and welcome to the iAcessAlpha Virtual Best Ideas winter ...

AskBio’s AB-1005 and AB-1002 Receive Pioneering Regenerative Medical Product Designation in Japan

Berlin, Germany, and Research Triangle Park, N.C., USA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Not intended for UK Media Product designation ...

BioInvent Presents Impressive Response Data from Ongoing Phase 2a Trial of Triple Combination BI-1206, Rituximab, and Calquence in r/r NHL at ASH 2025

Early data indicate that BI-1206 has the potential to reset one of the main resistance mechanisms to rituximab 47% of ...

New data shows RSV shots prevent ‘most dangerous’ respiratory infection for newborns

Respiratory syncytial virus, or RSV, has long been the leading cause of infant hospitalization in Canada. While real-world ...
BC Technology

How AbCellera Grew From a UBC Lab to a Global Biotech Company

It didn't look like the beginning of a global biotech company. In 2012, six scientists working in a corner of a UBC lab were developing technology they believed could transform how new medicines are ...

OmniAb Enters into a Technology License and Services Agreement for Antibody Discovery with a Newly-Formed Incubated Company of ArrowMark Partners and Viking Global Investors

OmniAb, Inc. (NASDAQ: OABI) and ArrowMark Partners (“ArrowMark”) today announced the signing of a license and services agreement for novel OmniAb-derived antibody discovery programs with Mabtrx ...